Pahl Heike L
Division of Experimental Anaesthesiology, University Hospital Freiburg, Center for Clinical Research, Breisacher Street 66, 79106 Freiburg, Germany.
Curr Hematol Rep. 2003 May;2(3):231-6.
During the past 4 years, the first molecular markers for polycythemia vera (PV) have been described. These markers include decreased expression of the thrombopoietin receptor c-Mpl, increased expression of the surface receptor polycythemia rubra vera-I, and insulin-like growth factor-I hypersensitivity. Characterization of these abnormalities has allowed the development of the first molecular diagnostic tools for PV. However, despite these advances, the molecular mechanisms leading to the development of PV remain poorly understood. This review summarizes and evaluates recent advances in our understanding of molecular aberrations in PV.
在过去4年里,已经描述了真性红细胞增多症(PV)的首批分子标志物。这些标志物包括血小板生成素受体c-Mpl的表达降低、真性红细胞增多症表面受体-I的表达增加以及胰岛素样生长因子-I超敏反应。对这些异常情况的表征使得能够开发出用于PV的首批分子诊断工具。然而,尽管有这些进展,导致PV发生的分子机制仍知之甚少。本综述总结并评估了我们对PV分子畸变理解的最新进展。